Abstract library

12 results for "Halfdanarson".
#218 Survival Analyses of Pancreatic Neuroendocrine Tumors: Contrasting Institutional Databases with Population-Based Registries
Introduction: Prognostic data in pancreatic NETs derives from population-based studies, as well as from institutional databases.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
#395 Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) in North American Cohort of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)
Introduction: PRRT is an accepted treatment in Europe for patients (pts) with mNETs, but considered investigational in the USA.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Boris Naraev
#401 Status of DNA Repair and Cell Proliferation Markers in High Grade Neuroendocrine Carcinoma of the Uterine Cervix (cNEC) Compared to Small Cell Carcinoma of the Lung (SCLC)
Introduction: Most patients (pts) with cNEC are treated with chemotherapy regimens used for SCLC due to both tumors’ histological similarity and aggressive behavior.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Boris Naraev
#402 Single-Center Treatment Outcomes in Patients (pts) with High Grade Neuroendocrine Carcinoma of the Uterine Cervix (cNEC)
Introduction: cNEC is a rare and aggressive cancer; the best treatment is unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Boris Naraev
#439 Chromogranin A (CgA) and Pancreastatin (PcSt) as Predictors of Peptide Receptor Radionuclide Therapy (PRRT) Outcomes in Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)
Introduction: CgA and PcSt are widely used in assessing response to treatment in mNETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Nancy Sharma
#457 Comparison of Transarterial Liver-Directed Therapies (LDT) for Low-Grade Metastatic Neuroendocrine Tumors (mNETs)
Introduction: Transarterial LDT can ameliorate symptoms and improve time to tumor progression (TTP) in mNETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Eric Engelman
#495 Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors (PNETs): Updated Results From a Single-Center Case Control Study
Introduction: PNETs are uncommon and little is known about risk factors and association with other cancers.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Thorvardur Halfdanarson
#1430 Cystic Neuroendocrine Tumors of the Pancreas (c-pNETs): A Single-Center Experience.
Introduction: c-pNETs are rare and may be less aggressive than their solid counterparts
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Thorvardur Halfdanarson
#1651 Renal Neuroendocrine Tumors (rNETs): A Single-Center Experience.
Introduction: rNETs are rare tumors and little is known about their natural history.
Conference: 14th Annual ENETS conference (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Dr. Thorvardur Halfdanarson
Keywords: Renal, Kidney, NET, Carcinoid
#1905 Pancreatic Neuroendocrine Tumors (pNETs): A Population-Based Analysis of Epidemiology and Outcomes.
Introduction: pNETs are rare and outcomes vary by stage, grade and presentation. The incidence and stage at diagnosis is changing
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Gustavo Westin